Navigation Links
Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Date:12/4/2007

CAMBRIDGE, Mass., Dec. 4 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announces the acceptance of four abstracts for presentation at the American Society for Clinical Pharmacology and Therapeutics annual meeting to be held April 2-5, 2008. The Society is the largest scientific and professional organization serving the discipline of clinical pharmacology.

These abstracts address the basis for adverse event outcomes and other key findings in previous surgical studies of Hemopure. Biopure and the collaborating scientists also address the safety and efficacy of both Hemopure and Hemoglobin-based oxygen carriers (HBOCs) in general. The titles, authors and affiliations are as follows:

RISK OF ADVERSE OUTCOME DUE TO ACUTE ANEMIA IN THE ORTHOPEDIC SURGICAL SETTING. L. B. Pearce, A. N. Pitman; Biopure Corporation, Cambridge, MA.

BREAKING THE RULES: MISINTERPRETATION OF DOSE-RESPONSE RELATIONSHIPS IN CLINICAL TRIALS. L. B. Pearce, A. N. Pitman, A. G. Greenburg; Biopure Corporation, Cambridge, MA.

A FLEXIBLE OUTCOME SCORING SYSTEM FOR CLINICAL TRIALS. A. N. Pitman, L. B. Pearce; Biopure Corporation, Cambridge, MA.

APPLICATION OF A UNIQUE SCORING SYSTEM FOR NUMERICAL DETERMINATION OF A BENEFIT RISK RATIO IN CLINICAL TRIALS. L. B. Pearce(1), A. Pitman,(1) A. G. Greenburg,(1) D. A. Freilich,(2) L. Kaplan(3); (1)Biopure Corporation, Cambridge, MA, (2)Naval Medical Research Center, Silver Spring, MD, (3)Yale University School of Medicine, New Haven, CT.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for several other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin.

Contact: Tiana Gorham Herb Lanzet (Investors)

Biopure Corporation H.L. Lanzet Inc.

(617) 234-6826 (212) 888-4570

IR@biopure.com lanzet@aol.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
5. Scientists Probe Sepsis Deadly Secrets
6. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
7. Scientists Develop Natural Protection for Stored Foods
8. Scientists detect presence of marburg virus in african fruit bats
9. Scientists Spot Brains Free Will Center
10. Scientists ID Likely Culprit in Popcorn Lung
11. Scientists explain how insulin secreting cells maintain their glucose sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... McKinney, Texas (PRWEB) , ... February 24, 2017 , ... ... south to The Medical Center at Craig Ranch building at 8080 State Highway 121, ... Ranch Medical District with easy access to Highway 121. , As the practice has ...
(Date:2/24/2017)... Abilene, Texas (PRWEB) , ... February 24, 2017 , ... ... article that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an ... of this current generation. He explains that the Bible details the current times ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... specializes in thought leadership , media relations, social media, content marketing and ... will be powered through Act-On, an intuitive marketing automation platform. , Rosica will ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, 2017 ... letter to withdraw previous guidance issued by the Obama Administration requiring schools ... in May 2016 by the Obama Administration came in response to a growing ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 Juan Monteverde , ... PC , a boutique securities firm headquartered at the ... , announces that a class action lawsuit has ...  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or ... securities between July 23, 2015 and December 30, 2016, inclusive ...
(Date:2/24/2017)... MELBOURNE , Australien, 24. Februar 2017 /PRNewswire/ ... innovatives, diversifiziertes Unternehmen des Gesundheitsbereiches, ist erfreut, für ... Vergleich mit dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen ... BioMedical und Aktualisierung zum Wachstum" finden Sie ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: ...
(Date:2/24/2017)... Feb. 23, 2017  This report analyzes the worldwide ... following Products: Intermediates, Analytical, and Others. ... include Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive ... Europe , and Rest of World. ... 2015 through 2022. Also, a six-year historic analysis is ...
Breaking Medicine Technology: